TG-43U1 parameterization of elongated RadioCoil 103Pd brachytherapy sources

Journal of Applied Clinical Medical Physics

Volumn 8, Issue 3, 2007, Pages 60-75

  Dini, Sharifeh A ^a   Awan, Shahid B ^a   Dou, Kai ^a   Meigooni, Ali S ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

103Pd; Brachytherapy; Elongated sources; Linear source; RadioCoil

Indexed keywords

EID: 34548209872     PISSN: None     EISSN: 15269914     Source Type: Journal    
DOI: 10.1120/jacmp.v8i3.2435     Document Type: Article

References (24)

1. Nag S, Vivekanandam S, Martinez-Monge R. Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;39(3):667-670.
2. Tapen EM, Blasko JC, Grimm PD, et al. Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Ent J Radiat Oncol Biol Phys. 1998;42(5):1063-1067.
3. Al-Qaisieh B, Carey B, Ash D, Bottomley D. The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59(2):397-399.
4. Kunos CA, Resnick MI, Kinsella TJ, Ellis RJ. Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Brachytherapy. 2004;3(2):71-77.
5. Older RA, Synder B, Krupski TL, Glembocki DJ, Gillenwater JY. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. J Urol. 2001; 165(5):1590-1592.
6. Dawson JE, Wu T, Roy T, Gu JY, Kim H. Dose effects of seeds placement deviations from pre-planned positions in ultrasound guided prostate implants. Radiother Oncol. 1994;32(3):268-270.
7. 125I prostate implants. Int J Radiat Oncol Biol Phys. 1996;34(3):717-725.
8. 103Pd wire line source for use in permanent brachytherapy implants. Med Phys. 2004; 31(11):3095-3105.
9. Hartford AC, Gladstone DJ, Seigne JD, Marshall JF, Rogers CC, Hug EB. First report on the clinical use of palladium- 103 coils: safety and efficacy in the brachytherapy treatment of early stage prostate cancer [Abstract]. Int J Radiat Oncol Biol Phys. 2005;63(2 Suppl 1):S319-S320.
10. Rivard MJ, Coursey BM, DeWerd LA, et al. Update of AAPM Task Group No. 43 report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31(3):633-674.
11. 103Pd brachytherapy source. J Appl Clin Mod Phys. 2005; 6(3):23-36.
12. Awan SB, Meigooni AS, Mokhberiosgouei R, Hussain M. Evaluation of TG-43U1 recommended 2D-anisotropy function for elongated brachytherapy sources. Med Phys. 2006;33(11):4271-4279.
13. Meigooni AS, Awan SB, Dou K. Feasibility of calibrating elongated brachytherapy sources using a well-type ionization chamber. Med Phys. 2006;33(11):4184-4189.
14. Meigooni AS, Sowards K, Soldano M. Dosimetric characteristics of the InterSource103 palladium brachytherapy source. Med Phys. 2000;27(5):1093-1100.
15. 103Pd brachytherapy source. Med Phys. 2001;28(12):2568-2575.
16. 125I brachytherapy source. Med Phys. 2002;29(9):2152-2158.
17. 169Yb sources. Med Phys. 2006;33(6):1729-1737.
18. 125P brachytherapy sources. Appl Radiat Isot. 2004; 61(6):1443-1450.
19. X-5 Monte Carlo Team. MCNP - a general Monte Carlo N-particle transport code. Ver.5. Los Alamos National Laboratory Report BNL-NCS-17541. 8th edition. Los Alamos (NM): Los Alamos National Laboratory; 2000.
20. Cross Section Evaluation Worldng Group. ENDF/B-VI Summary Documentation. ENDF-201. Brookhaven National Laboratory Report BNL-NCS-17541. 8th edition. Upton (NY): National Nuclear Data Center; 2000.
21. Hubbell JH, Seltzer SM. Tables of X-ray mass attenuation coefficients and mass energy absorption coefficients [Web resource]. Ver. 1.4. Gaithersburg (MD): National Institute of Standards and Technology; 1996 (update: 2004). [Available at: physics.nist.gov/xaamdi; cited 10January 2006]
22. 103Pd brachytherapy seeds. J Res Nad Inst Stand Technol. 2003; 108(5):337-358.
23. 103Pd interstitial brachytherapy source. Med Phys. 2000;27(4):643-654.
24. 103Pd sources. Med Phys. 1998;25(12):2271-2278.